Hansoh Pharmaceutical Group Co Ltd
03692
Company Profile
Business description
Hansoh Pharmaceutical Group Co Ltd is an investment holding company. The company were principally engaged in the research and development, production and sale of a series of pharmaceutical products in the People's Republic of China. It focuses on disease therapeutic areas such as oncology, anti-infectives, CNS, metabolism and immunology. The majority of Group's revenue was generated from the sale of pharmaceutical products in Chinese mainland.
Contact
No. 287 Xiangke Road
Pudong New Area
Shanghai
CHNT: +86 4008285227
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
9,347
Stocks News & Analysis
stocks
Ask the analyst: Where does GYG stand following its US exit?
All roads lead back home for Guzman Y Gomez.
stocks
Chart of the Week: The long term headwinds facing copper shares
The key factors challenging the bull case for copper demand.
stocks
Australia’s oldest REIT undervalued
This REIT remains undervalued as trophy properties shine through.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,922.40 | 0.70 | 0.01% |
| CAC 40 | 8,337.29 | 66.70 | -0.79% |
| DAX 40 | 25,040.28 | 44.47 | 0.18% |
| Dow JONES (US) | 52,305.24 | 13.96 | -0.03% |
| FTSE 100 | 10,478.34 | 18.78 | -0.18% |
| HKSE | 23,154.41 | 273.39 | 1.19% |
| NASDAQ | 26,040.03 | 173.69 | -0.66% |
| Nikkei 225 | 69,264.46 | 1,210.50 | -1.72% |
| NZX 50 Index | 13,525.52 | 84.98 | -0.62% |
| S&P 500 | 7,483.23 | 16.13 | -0.22% |
| S&P/ASX 200 | 8,718.30 | 7.70 | 0.09% |
| SSE Composite Index | 4,075.31 | 37.13 | -0.90% |